Literature DB >> 24801688

TGFβ activated kinase 1 (TAK1) at the crossroad of B cell receptor and Toll-like receptor 9 signaling pathways in human B cells.

Dániel Szili1, Zsuzsanna Bankó1, Eszter Angéla Tóth1, György Nagy2, Bernadette Rojkovich3, Tamás Gáti3, Melinda Simon1, Zoltán Hérincs1, Gabriella Sármay1.   

Abstract

B cell development and activation are regulated by combined signals mediated by the B cell receptor (BCR), receptors for the B-cell activating factor of the tumor necrosis factor family (BAFF-R) and the innate receptor, Toll-like receptor 9 (TLR9). However, the underlying mechanisms by which these signals cooperate in human B cells remain unclear. Our aim was to elucidate the key signaling molecules at the crossroads of BCR, BAFF-R and TLR9 mediated pathways and to follow the functional consequences of costimulation.Therefore we stimulated purified human B cells by combinations of anti-Ig, B-cell activating factor of the tumor necrosis factor family (BAFF) and the TLR9 agonist, CpG oligodeoxynucleotide. Phosphorylation status of various signaling molecules, B cell proliferation, cytokine secretion, plasma blast generation and the frequency of IgG producing cells were investigated. We have found that BCR induced signals cooperate with BAFF-R- and TLR9-mediated signals at different levels of cell activation. BCR and BAFF- as well as TLR9 and BAFF-mediated signals cooperate at NFκB activation, while BCR and TLR9 synergistically costimulate mitogen activated protein kinases (MAPKs), ERK, JNK and p38. We show here for the first time that the MAP3K7 (TGF beta activated kinase, TAK1) is responsible for the synergistic costimulation of B cells by BCR and TLR9, resulting in an enhanced cell proliferation, plasma blast generation, cytokine and antibody production. Specific inhibitor of TAK1 as well as knocking down TAK1 by siRNA abrogates the synergistic signals. We conclude that TAK1 is a key regulator of receptor crosstalk between BCR and TLR9, thus plays a critical role in B cell development and activation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24801688      PMCID: PMC4011794          DOI: 10.1371/journal.pone.0096381

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  73 in total

1.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

2.  Distinct profiles of human B cell effector cytokines: a role in immune regulation?

Authors:  Martin E Duddy; Andrea Alter; Amit Bar-Or
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

3.  Key developmental transitions in human germinal center B cells are revealed by differential CD45RB expression.

Authors:  Stephen M Jackson; Natessa Harp; Darshna Patel; Jordan Wulf; Erich D Spaeth; Uzoamaka K Dike; Judith A James; J Donald Capra
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

4.  BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells.

Authors:  Lingchen Fu; Yen-Chiu Lin-Lee; Lan V Pham; Archito T Tamayo; Linda C Yoshimura; Richard J Ford
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

5.  Restoration of tolerance in lupus by targeted inhibitory receptor expression.

Authors:  Tracy L McGaha; Brian Sorrentino; Jeffrey V Ravetch
Journal:  Science       Date:  2005-01-28       Impact factor: 47.728

6.  Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10.

Authors:  A O'Garra; G Stapleton; V Dhar; M Pearce; J Schumacher; H Rugo; D Barbis; A Stall; J Cupp; K Moore
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

7.  Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase.

Authors:  Parameswaran Ramakrishnan; Wangxia Wang; David Wallach
Journal:  Immunity       Date:  2004-10       Impact factor: 31.745

8.  Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help.

Authors:  Hendrik Poeck; Moritz Wagner; Julia Battiany; Simon Rothenfusser; Daniela Wellisch; Veit Hornung; Bernd Jahrsdorfer; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

9.  TAK1 activation for cytokine synthesis and proliferation of endometriotic cells.

Authors:  Fuminori Taniguchi; Tasuku Harada; Hiroko Miyakoda; Tomio Iwabe; Imari Deura; Yukiko Tagashira; Ayako Miyamoto; Ayako Watanabe; Kana Suou; Takashi Uegaki; Naoki Terakawa
Journal:  Mol Cell Endocrinol       Date:  2009-05-03       Impact factor: 4.102

10.  The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway.

Authors:  Edina Schweighoffer; Lesley Vanes; Josquin Nys; Doreen Cantrell; Scott McCleary; Nicholas Smithers; Victor L J Tybulewicz
Journal:  Immunity       Date:  2013-02-28       Impact factor: 31.745

View more
  10 in total

1.  Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.

Authors:  Allison K Ehrlich; Olga L Fernández; Daniel Rodriguez-Pinto; Tiago M Castilho; Maria J Corral Caridad; Karen Goldsmith-Pestana; Nancy Gore Saravia; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

2.  Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19.

Authors:  Dániel Szili; Marcell Cserhalmi; Zsuzsanna Bankó; György Nagy; David E Szymkowski; Gabriella Sármay
Journal:  MAbs       Date:  2014-04-23       Impact factor: 5.857

3.  Toll-Like Receptor 9-Dependent AMPKα Activation Occurs via TAK1 and Contributes to RhoA/ROCK Signaling and Actin Polymerization in Vascular Smooth Muscle Cells.

Authors:  Cameron G McCarthy; Camilla F Wenceslau; Safia Ogbi; Theodora Szasz; R Clinton Webb
Journal:  J Pharmacol Exp Ther       Date:  2018-01-18       Impact factor: 4.030

4.  Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response in older individuals.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Michael T Zimmermann; Diane E Grill; Ann L Oberg; Gregory A Poland
Journal:  Vaccine       Date:  2016-06-20       Impact factor: 3.641

Review 5.  TLR7/TLR9- and B Cell Receptor-Signaling Crosstalk: Promotion of Potentially Dangerous B Cells.

Authors:  Amy N Suthers; Stefanie Sarantopoulos
Journal:  Front Immunol       Date:  2017-07-13       Impact factor: 7.561

6.  Complement Receptor Type 1 (CR1, CD35), the Inhibitor of BCR-Mediated Human B Cell Activation, Differentially Regulates TLR7, and TLR9 Induced Responses.

Authors:  Bernadett Mácsik-Valent; Katinka Nagy; László Fazekas; Anna Erdei
Journal:  Front Immunol       Date:  2019-07-02       Impact factor: 7.561

Review 7.  NF-κB: At the Borders of Autoimmunity and Inflammation.

Authors:  Laura Barnabei; Emmanuel Laplantine; William Mbongo; Frédéric Rieux-Laucat; Robert Weil
Journal:  Front Immunol       Date:  2021-08-09       Impact factor: 7.561

8.  Expression of Concern: TGFβ Activated Kinase 1 (TAK1) at the Crossroad of B Cell Receptor and Toll-Like Receptor 9 Signaling Pathways in Human B Cells.

Authors: 
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

Review 9.  The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells.

Authors:  Jialing Liu; Qiuli Liu; Xiaoyong Chen
Journal:  Front Immunol       Date:  2020-08-14       Impact factor: 7.561

10.  Phosphorylation of the multifunctional signal transducer B-cell adaptor protein (BCAP) promotes recruitment of multiple SH2/SH3 proteins including GRB2.

Authors:  Johannes U Lauenstein; Atul Udgata; Alex Bartram; Delphine De Sutter; David I Fisher; Samer Halabi; Sven Eyckerman; Nicholas J Gay
Journal:  J Biol Chem       Date:  2019-09-16       Impact factor: 5.157

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.